Find the Pfizer Inc. style guide with brand assets such as logos, colors, fonts, and more.

We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s...

2021年4月28日 · Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types i.

Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates

2021年4月29日 · Fosmanogepix是Amplyx正在开发的用于治疗侵袭性真菌感染的一线药物，包括具有高度耐药性的金假丝酵母菌、金假丝酵母菌。 除了假丝酵母外，Fosmanogepix还被...

2021年4月29日 · Amplyx的主要化合物Fosmanogepix（APX001）是用于治疗侵袭性真菌感染的新型研究资产。 每年全世界范围内发生超过150万例侵袭性真菌感染病例，在不同类型的感染中死亡率高达30-80％。

Amplyx was founded with the mission to develop innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems. Amplyx is advancing development programs with the potential to protect these vulnerable patients, including those with cancer and transplants, and the critically ill.

2020年12月14日 · Amplyx Pharmaceuticals is developing treatments to defeat life-threatening diseases caused by life-saving treatments and allow patients to stay on the path to their cure. Learn more about their ongoing work: Our drug development pipeline is focused on developing therapies that overcome life-threatening diseases caused by life-saving therapies.

2021年4月28日 · (RTTNews) - Pfizer Inc. (PFE) has acquired privately held Amplyx Pharmaceuticals, Inc., the company announced in a release. The acquisition, financial terms of which are not disclosed, follows an...

2021年4月28日 · Pfizer Inc (PFE.N) on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant "superbug" fungal infections in patients with...